Advanced Search


The leading alpha1 augmentation therapy for 20 years is now improved

  • Shorter Infusion Time: delivers twice the active protein per milliliter as Prolastin, cutting infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min
  • Higher Purity: delivers ≥ 90% pure Alpha-1 protein allowing it to be more concentrated than Prolastin

Find out more about new PROLASTIN-C

Smoking accelerates lung function decline in Alphas1

Smoking/Lung function decline graph

Mean annual decline in FEV1 in 208 never-smokers, 697 ex-smokers, and 22 current smokers with severe Alpha-1 1

  • In a registry study of 927 patients with Alpha-1, 78.7% of patients were either current smokers (8.1%) or ex-smokers (70.6%)1

Oxidant-mediated stress damages lungs5

Smoking/Oxidative stress on lungs

Cigarette smoke2,3:

  • Contains oxidants capable of inactivating AAT2
  • Recruits inflammatory cells and increases neutrophil elastase concentration5

Passive smoking can be detrimental to lung function2,4

Help Alphas learn how to quit smoking. Get information from the American Lung Association.

Help Alphas stay healthy. Download Managing Environmental Risk Factors, a brochure from AlphaNet that you can share with your patients.

next: Patient Education & Support for Alphas >

Important Safety Information

PROLASTIN-C, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to deficiency of alpha1-proteinase inhibitor (alpha1-antitrypsin deficiency). The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials. PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe Alpha1-PI deficiency has not been established.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. PROLASTIN-C is contraindicated in patients with antibodies against IgA.

The most common drug related adverse reactions during clinical trials in ≥ 1% of subjects were chills, malaise, headache, rash, hot flush, and pruritus.

PROLASTIN-C is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying PROLASTIN-C Full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

References
  1. Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1998;158(1):49-59.
  2. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900.
  3. DeMeo DL, et al. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax. 2007;62(9):806-813.
  4. Mayer AS, Stoller JK, Vedal S, et al. Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2007;1(4):485-492.
  5. MacNee W. Chest. 2000;117(5 suppl 1):303S-317S. Copyright 2000 by American College of Chest Physicians. Reproduced with permission of American College of Chest Physicians via Copyright Clearance Center.
  6. PROLASTIN-C [package insert]. Grifols.